Thromboembolism constitutes a common complication of various diseases in dogs and cats,im-pacting either arteries or veins and generally associated with a poor prognosis.The range of antithrombotic drugs currently available for veterinary clinical prevention and treatment of thromboembolism is limited,which affects the level of clinical diagnosis and treatment.The introduction of new drugs in this field is of practical significance.Rivaroxaban,a novel non-vitamin K-dependent antagonist oral anticoagulant,has been proven to specifically inhibit the activity of coagulation factor X,thereby preventing thrombus formation.Recent years have seen a growing body of clinical research on rivaroxaban in human medicine,involving its sole use or in combination with dual-pathway inhibition therapy for the prevention and treatment of various types of arterial and venous thromboembolisms.This expanding research provides a solid basis for its appli-cation in veterinary medicine.Studies on the use of rivaroxaban in dogs and cats are progressively being un-dertaken.This paper provides an overview of the incidence and current state of prevention and treatment of thromboembolic diseases in dogs and cats,the pharmacological characteristics of rivaroxaban,and its clini-cal trial progress in both human and veterinary medicine.The aim is to furnish a reference for further re-search on the use of rivaroxaban in veterinary clinical practice.
维普
万方数据